Sanofi Oncology

mClinica develops mobile platforms that strengthen the pharmaceutical supply chain, generate data, improve patient adherence to medication, and build the capacity of the pharmacy workforce. Since 2017, mClinica has connected 150,000 pharmacy professionals and 40,000 pharmacies through a single digital channel. Their users reach approximately 150 million patients each month. mClinica currently operates across Indonesia, Philippines, Vietnam, Cambodia, Thailand, Malaysia, and Singapore with capacity for expansion. Their team is composed of over 120 team members including experts in public health, data science, and pharmacy. mClinica is supported by impact investors like the Global Innovation Fund (backed by USAID, UKAID, DFAT, Swedish Government, and the Omidyar Network) and Patamar Capital (formerly Unitus Impact) as well as other investors from the US, Europe, and Asia. mClinica implements projects both digitally and on the ground to connect the world’s pharmacies and transform global health. mClinica follows a social enterprise business model in which they seek double-bottom line returns – maximizing both financial returns and social impact. mClinica’s rapid growth and success is increasingly recognized. mClinica was the recipient of the Data Driven Apps Award of the World Government Summit in 2019, USAID-FHI360 Data for Resilience Award, Pierre Fabre Foundation Prize for eHealth Innovation, and Hack Osaka. The company has consistently been recognized as one of the most innovative startups in healthcare in Asia Pacific.

Innovent Biologics, Inc. is a prominent biopharmaceutical company based in Suzhou, China, specializing in the discovery, development, manufacture, and commercialization of monoclonal antibody drug candidates. The company focuses on various therapeutic areas, including oncology, ophthalmology, immunology, and metabolic diseases. Its flagship product, Tyvyt (sintilimab), is an anti-PD-1 monoclonal antibody used in treating multiple cancers and is featured on the National Reimbursement Drug List. Innovent has developed several other promising candidates, including biosimilars and bispecific antibodies for conditions such as non-Hodgkin’s lymphoma, autoimmune diseases, and advanced solid tumors. The company has established strategic collaborations with major global pharmaceutical firms, enhancing its research and development capabilities. Founded in 2011, Innovent has a strong management team with extensive experience in biologics, and it continues to expand its portfolio of therapeutic options while maintaining a commitment to innovation in the biopharmaceutical industry.

Areteia Therapeutics is a biotechnology company focused on improving the management of eosinophilic asthma through an innovative oral drug treatment. The company, which emerged from Knopp, aims to provide patients with a novel therapeutic option that inhibits the maturation of eosinophils—cells that can cause airway damage in asthma patients. Its drug candidate has demonstrated promising results in a phase 2 clinical trial, which showed a reduction in blood eosinophil counts, indicating enhanced lung function. This approach seeks to empower patients by offering a potentially effective and accessible treatment for a severe form of asthma, thereby improving their quality of life and disease management.

Exscientia is applying AI and big data processing to accelerate drug discovery and development. At the forefront of small molecule drug discovery. They are the first company to automate drug design, surpassing conventional human endeavor. Their AI-driven systems actively learn best practice from vast repositories of discovery data and are further enhanced with knowledge acquired from seasoned drug hunters. With better information to hand than any researcher could acquire individually, their knowledge-driven systems design millions of novel, project-specific compounds and pre-assess each for predicted potency, selectivity, ADME and other key criteria. From this, a selection of the best, information-rich compounds are selected for synthesis and assay. With new experimental data generated, the results are integrated and the next design cycle initiated. Rapid design-make-test cycles ensure unparalleled progress towards desired project goals. Exscientia has already delivered exceptional productivity, generating candidates in roughly one-quarter of the time of traditional approaches.

Owkin is an artificial intelligence company founded in 2016, with headquarters in New York and an additional office in Paris. The company focuses on developing machine learning software for medical research, enabling researchers to test AI models on distributed data. Owkin's offerings include Owkin Lab, which facilitates data connectivity by therapeutic area; Owkin Loop, which provides validated and packaged models; and a comprehensive software stack for full-stack services. The company currently has 30 live models and an additional 40 in development. Owkin aims to empower medical researchers in hospitals, universities, and pharmaceutical companies to better understand variations in drug efficacy among patients, enhance the drug development process, and identify optimal treatments for individual patients, ultimately improving treatment outcomes. The company is supported by various investors and has a scientific board to guide its research initiatives.

Gyroscope is an ophthalmology company developing gene therapies for the treatment of eye diseases linked to an unbalanced complement system. Gyroscope was founded to explore the convergence of advancements made in the understanding of the complement system’s impact on eye disease, the genetic basis of Age-related Macular Degeneration (AMD) and gene therapy as a mode of treatment delivery.

Translate Bio is a clinical-stage biotechnology company based in Lexington, Massachusetts, that focuses on developing messenger RNA (mRNA) therapeutics aimed at treating diseases linked to protein or gene dysfunction. Since its founding in 2011, the company has been working on innovative treatments, including MRT5005, which is currently undergoing Phase I/II clinical trials for cystic fibrosis, and MRT5201, intended for the treatment of ornithine transcarbamylase deficiency. Translate Bio aims to create transformative medicines that address unmet medical needs in rare diseases.

Tidal Therapeutics is a preclinical biotech company based at LabCentral in Cambridge, MA. The company is focused on developing nanoparticles that deliver mRNA to reprogram immune cells inside the body with applications in oncology and immune diseases.

Novadiscovery SAS, established in 2010 and located in Lyon, France, specializes in the development of Jinko, an in silico clinical trial simulation platform. This innovative platform assists pharmaceutical and biotechnology companies in conducting virtual trials, allowing them to predict the clinical benefits of new drugs prior to human testing. Jinko focuses on various therapeutic areas, including immuno-oncology, orphan diseases, metabolic diseases, and cardiotherapy. By utilizing advanced mathematics and intelligent algorithms, Novadiscovery creates a community of virtual patients, enabling researchers to optimize drug discovery processes, reduce risks, and minimize costs associated with bringing new drugs to market.

Kymab Limited is a biotechnology company based in Cambridge, United Kingdom, that specializes in the discovery, development, and commercialization of human monoclonal antibody therapeutics. Utilizing its proprietary Kymouse platform, Kymab captures the diversity of the human immune system's B lymphocyte component to generate biopharmaceuticals targeting both established and novel drug targets. The company's therapeutic focus spans immuno-oncology, immunology, and other opportunistic areas. Kymab has established strategic collaborations with Heptares Therapeutics and LifeArc to enhance its research and development efforts. Founded in 2009, Kymab continues to advance its pipeline of monoclonal antibody candidates aimed at addressing significant medical needs.

Kiadis Pharma N.V. is a biopharmaceutical company based in Amsterdam, specializing in cell-based immunotherapy products for blood cancer treatment. The company is developing K-NK002, currently in Phase II clinical trials, as an adjunctive immunotherapeutic for blood cancer patients undergoing haploidentical hematopoietic stem cell transplantation with the post-transplant cyclophosphamide protocol. K-NK003 is another product in Phase I/II trials, targeting patients with acute myeloid leukemia relapse or refractory cases. Additionally, Kiadis Pharma is working on K-NK00X, a preclinical NK-cell therapy candidate aimed at treating various solid tumors. The company has established collaborations for the development of a combination therapy involving monoclonal antibodies and natural killer cells to address COVID-19. Kiadis Pharma focuses on addressing the complications and limitations associated with hematopoietic stem cell transplants, offering novel treatment options for terminally ill cancer patients with significant unmet medical needs.

Principia Biopharma Inc. is a late-stage biopharmaceutical company based in South San Francisco, California, focused on developing innovative therapies for immune-mediated diseases. The company's lead candidate, rilzabrutinib, is an inhibitor currently undergoing Phase III clinical trials for pemphigus and pemphigus foliaceus, as well as Phase 1/2 and Phase 2 trials for immune thrombocytopenia and IgG4-related disease, respectively. Additionally, Principia is advancing PRN2246/SAR442168, aimed at treating multiple sclerosis and other central nervous system disorders, which is in Phase II trials. Another candidate, PRN473, is in Phase I trials for various immune-mediated diseases. Principia Biopharma collaborates with Genzyme Corporation to explore treatments for relapsing and progressive multiple sclerosis, enhancing its commitment to addressing significant unmet medical needs in immunology and oncology. Established in 2008, the company operates as a subsidiary of Sanofi.

Synthorx, Inc. is a biopharmaceutical company based in La Jolla, California, that specializes in developing innovative protein therapeutics through synthetic biology. The company focuses on creating novel cytokine Synthorin programs aimed at treating cancer and autoimmune disorders. Its lead candidate, THOR-707, is a modified version of recombinant human IL-2 being tested for various solid tumors, both as a monotherapy and in combination with immune checkpoint inhibitors. Additionally, Synthorx is developing Synthorins for other indications, including IL-10 for immuno-oncology and IL-15 as an immunoregulatory cytokine. The company leverages proprietary engineered organisms to produce these advanced proteins with high fidelity, enhancing their efficacy, safety, and convenience for patients. Founded in 2014 with technology licensed from The Scripps Research Institute, Synthorx has attracted investment from various venture capital firms and operates as a subsidiary of Sanofi.

Icosavax, Inc. is a biotechnology company based in Seattle, Washington, founded in 2017. It specializes in the development of vaccines using computationally designed virus-like particles (VLPs). The company's primary focus is on creating safe and effective vaccines to address significant unmet medical needs in the realm of infectious diseases, particularly life-threatening respiratory illnesses. One of its key vaccine candidates is IVX-121, aimed at protecting older adults from respiratory syncytial virus (RSV) disease. Icosavax leverages exclusive technology licensed from the Institute for Protein Design at the University of Washington to advance its innovative vaccine solutions.

Veralox Therapeutics specializes in the development of small molecule therapeutics aimed at addressing the underlying causes of thrombosis and type one diabetes. By leveraging a deep understanding of the molecular mechanisms associated with these conditions, the company seeks to create innovative treatment options that can lead to improved health outcomes for patients. Their focus includes therapies specifically targeting heparin-induced thrombocytopenia and thrombosis, with the goal of providing patients with effective solutions for complete recovery from diabetes and associated complications.

Aetion, Inc. develops a science and analytics platform to assess real-world evidence (RWE) from a range of sources. The company offers Aetion Evidence Platform, a platform that generates RWE needed by healthcare decision makers to engage in value-based care. Its solution allows payers, providers, medical device makers, biopharma customers, and academic institutions to analyze data from various clinical and financial interactions in healthcare, including claims, electronic health records, registries, and clinical trials. The company’s platform is also used in database analytics and comparative effectiveness courses taken by epidemiologists, outcomes researchers, health economists, and biostatisticians. It serves customers worldwide. Aetion, Inc. has a strategic collaboration with McKesson. The company was founded in 2012 and is based in New York, New York.

BioNTech is a biotechnology company focused on developing and commercializing immunotherapies for cancer and infectious diseases. Founded in 2008 and headquartered in Mainz, Germany, the company has pioneered innovative therapies through advanced computational discovery and drug development platforms. BioNTech's oncology pipeline includes various neoantigen-targeted therapies, such as NEO-PV-01 for advanced non-small cell lung cancer and multiple FixVac product candidates for different cancers, including melanoma, prostate cancer, and HPV-positive head and neck cancers. The company also explores mRNA vaccine candidates for infectious diseases and maintains collaborations with prominent pharmaceutical firms. BioNTech Cell & Gene Therapies GmbH, a subsidiary, specializes in developing T cell immunotherapies for cancer treatment.

Enable Injections, LLC develops a disposable body-worn bolus injector to deliver high viscosity/volume payloads to the subcutaneous tissue. The company’s system uses standard vial, syringe, or cartridge container closure; and automatically mixes lyophilized solutions. Its drug delivery system’s transfer package automatically warms the drug, and enables user to insert the container into the system, place the injector on the skin, and press the central button, as well as know the progress of the delivery through its viewing window, and then dispose the device. It also offers partial or multi-vial/syringe transfer systems for filling its LVWIs. The company was founded in 2010 and is based in Cincinnati, Ohio.

Eden Biologics is a biopharmaceutical company founded in 2012 and headquartered in Zhubei City, Taiwan. The company specializes in contract development and manufacturing services aimed at accelerating the development programs of its partners in the biopharmaceutical sector. It offers a comprehensive range of services, including cell line development, process development, analytical services, formulation development, and cGMP manufacturing. Eden Biologics is committed to making high-quality biologic medicines affordable and accessible by leveraging advanced process and engineering technologies that simplify and reduce the costs associated with mammalian cell culture manufacturing. The company operates state-of-the-art manufacturing facilities in Asia, adhering to US, EU, and ICH cGMP regulations, and is led by a team of experienced professionals with backgrounds in leading biopharmaceutical companies.

Fulcrum Therapeutics is a clinical-stage biopharmaceutical company based in Cambridge, Massachusetts, dedicated to developing innovative therapies for genetically defined diseases with high unmet medical needs. The company's lead product candidate, losmapimod, is a small molecule currently undergoing Phase 2b clinical trials for the treatment of facioscapulohumeral muscular dystrophy (FSHD), a progressive muscle-wasting disorder. Another key candidate, FTX-6058, aims to increase fetal hemoglobin levels in patients with sickle cell disease and beta-thalassemia. In addition to these programs, Fulcrum is exploring drug targets for other conditions such as Duchenne muscular dystrophy, Friedreich ataxia, myotonic dystrophy 1, and various neurological and pulmonary diseases. The company has established collaborations with Acceleron Pharma and MyoKardia to advance research and develop targeted therapies for pulmonary diseases and genetic cardiomyopathies, respectively. Founded in 2015, Fulcrum Therapeutics is committed to improving the lives of patients facing significant health challenges.

Ablynx NV is a clinical biopharmaceutical company based in Ghent, Belgium, that specializes in the discovery and development of Nanobodies, a novel class of therapeutic proteins derived from single-domain antibody fragments. The company focuses on addressing serious human diseases, including inflammation, hematology, oncology, and respiratory conditions. Ablynx has a diverse pipeline with approximately 25 projects, featuring five Nanobodies currently in clinical development. Notable clinical programs include caplacizumab for acquired thrombotic thrombocytopenic purpura, ALX-0171 for respiratory syncytial virus infection, and Vobarilizumab for rheumatoid arthritis and systemic lupus erythematosus. Other ongoing trials involve treatments for psoriasis, solid tumors, chronic kidney diseases, and bone-loss related disorders. Ablynx has established collaboration agreements with several major pharmaceutical companies to advance its research and development efforts. Founded in 2001, Ablynx was formerly known as MatchX and rebranded in 2002. The company operates as a subsidiary of Sanofi.

Bioverativ Inc. is a biopharmaceutical company focused on developing therapies for hemophilia and other rare blood disorders, including cold agglutinin disease, sickle cell disease, and beta thalassemia. Established in 2016 and based in Waltham, Massachusetts, the company is known for its innovative pipeline that includes less-frequent prophylactic dosing options for hemophilia A, subcutaneous dosing for hemophilia B, and gene therapy programs for both types of hemophilia. Additionally, Bioverativ is advancing Sutimlimab, a therapy aimed at selectively inhibiting the complement pathway of the immune system to treat cold agglutinin disease. As a subsidiary of Sanofi, Bioverativ is committed to transforming the lives of individuals affected by these chronic conditions through rigorous research, clinical trials, and the development of effective treatment methods.

Thermalin Diabetes, LLC is a biotechnology company based in Cleveland, Ohio, with an additional office in Newton, Massachusetts. Founded in 2010, the company specializes in developing insulin analogs for the treatment of Type 1 and Type 2 diabetes. Its product offerings include ultra-rapid acting insulin designed to be administered before meals to mitigate glucose spikes, as well as long-acting insulin to maintain basal glucose levels. Thermalin aims to innovate within the insulin market by introducing a highly concentrated, stabilized ultra-rapid acting insulin that can be used in a disposable glucose management system. This new insulin formulation also facilitates the factory-filling of reservoirs for existing insulin pumps. Additionally, the company is exploring partnerships to develop no-cold-chain basal and mixed insulins, as well as glucose-responsive insulins, to enhance patient compliance and treatment outcomes.

Eden Biologics is a biopharmaceutical company founded in 2012 and headquartered in Zhubei City, Taiwan. The company specializes in contract development and manufacturing services aimed at accelerating the development programs of its partners in the biopharmaceutical sector. It offers a comprehensive range of services, including cell line development, process development, analytical services, formulation development, and cGMP manufacturing. Eden Biologics is committed to making high-quality biologic medicines affordable and accessible by leveraging advanced process and engineering technologies that simplify and reduce the costs associated with mammalian cell culture manufacturing. The company operates state-of-the-art manufacturing facilities in Asia, adhering to US, EU, and ICH cGMP regulations, and is led by a team of experienced professionals with backgrounds in leading biopharmaceutical companies.

Onduo is a digital healthcare company that uses data to help people with diabetes live their best life.

Portal Instruments, Inc. is a clinical-stage medical device company based in Cambridge, Massachusetts, specializing in needle-free jet injectors for drug delivery. Founded in 2012, the company develops innovative technology that allows for the precise administration of medications through the skin without the use of needles. This platform is designed to accommodate various drug viscosities and concentrations, enhancing compatibility with pharmaceutical manufacturing processes. The jet injectors deliver medication via a narrow stream, ensuring a painless and silent experience for patients. Portal Instruments aims to replace traditional needles and syringes with its advanced delivery mechanism, making it applicable across multiple fields, including medical, agricultural, and cosmetic applications. The company is positioned to transform the drug delivery landscape and improve patient experiences for those managing chronic diseases.

MyoKardia, Inc. is a clinical-stage biopharmaceutical company dedicated to discovering, developing, and commercializing targeted therapies for rare cardiovascular diseases, particularly heritable cardiomyopathies and genetically-driven heart failure. Founded in 2012 and headquartered in Brisbane, California, the company focuses on addressing biomechanical defects in cardiac muscle contraction. Its lead product candidate, Mavacamten, is an orally administered allosteric modulator of cardiac myosin currently in Phase III clinical trials for hypertrophic cardiomyopathy (HCM). Additionally, MyoKardia is developing Danicamtiv, a small molecule that has completed Phase I and IIa trials for dilated cardiomyopathy. The company's preclinical pipeline includes programs targeting hypercontractility and impaired relaxation in HCM, as well as treatments for diastolic dysfunction. As of November 2020, MyoKardia operates as a subsidiary of Bristol-Myers Squibb Company.

Esperance Pharmaceuticals Inc. develops targeted anticancer drugs to treat women with ovarian and breast cancer. Its products include EP-100, an oncolytic peptide that seeks and destroys cancer cells that express receptors for luteinizing hormone releasing hormone (LHRH), and selectively kill cancer cells without harming normal cells. The company has strategic alliance with MD Anderson Cancer Center to accelerate clinical development of EP-100 for the treatment of women with ovarian cancer and breast cancer. Esperance Pharmaceuticals Inc. was incorporated in 2005 and is based in Houston, Texas.

Aventis S.A. is a prominent global pharmaceutical company focused on the discovery, development, manufacture, and marketing of branded prescription drugs and human vaccines. The company is recognized for its significant contributions to preventative medicine, particularly through its vaccines division, which offers a comprehensive range of vaccines that protect against various infectious diseases. In 2008, this division provided over 1.6 billion doses, successfully immunizing more than 500 million people worldwide. Aventis aims to address health challenges by delivering innovative therapeutic solutions and is a leader in the pharmaceutical and vaccine industries.